Home | My Profile | Contact Us
Research Trends Products  |   order gateway  |   author gateway  |   editor gateway  
Register | Forgot Password

Author Resources
 Author Gateway
 Article submission guidelines

Editor Resources
 Editor/Referee Gateway

 Regional Subscription Agents/Distributors
Current Topics in Pharmacology   Volumes    Volume 17  Issue 1
Current pharmacologic management strategies in aneurysmal subarachnoid hemorrhage
Margaret Riordan, Michele Kyle, Tonia Tiewul, Eric M. Deshaies, Mary Lou Vallano
Pages: 61 - 77
Number of pages: 17
Current Topics in Pharmacology
Volume 17  Issue 1

Copyright © 2013 Research Trends. All rights reserved

Aneurysmal subarachnoid hemorrhage (aSAH) is a particularly devastating neurologic insult as the majority of patients suffer morbidity and mortality at the time of rupture, and from subsequent complications. While at least one-third of patients die shortly after experiencing a ruptured cerebral aneurysm, ~60% of survivors develop debilitating neurologic deficits throughout their course of treatment. In numerous cases, spastic narrowing of large cerebral vessels, termed cerebral vasospasm, has been associated with delayed cerebral ischemia (DCI) and stroke 4 to 21 days post-hemorrhage. Despite decades of animal research and numerous clinical trials, highly effective pharmacological treatment options for aSAH patients are lacking. Herein, results from clinical trials examining pharmacologic therapies for delayed cerebral vasospasm, DCI and functional outcomes in aSAH patients are discussed, including the current status of nimodipine and other dihydropyridines, endothelin receptor antagonists, magnesium sulfate, and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins).
View Full Article  


Buy this article
Buy this volume
Subscribe to this title
Shopping Cart

Quick Links
Search Products
Browse in Alphabetical Order : Journals
Browse by Subject Classification : Journals

Ordering Information Ordering Information
Downloadable forms Downloadable Forms